Pharmaphorum interviewed VivoSense CEO Dudley Tabakin and new board members from Xontogeny and Debiopharm to discuss how VivoSense’s recent $25M Series A Financing round will help scale up VivoSense® software and accelerate the use of wearable sensors data in clinical trials.
Read More
